← Back to Search

Immune-mediated condition for Pemphigus Vulgaris

N/A
Recruiting
Led By Erin X Barrett, MD
Research Sponsored by University of Nebraska
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This study will examine the coagulation and fibrinolysis profiles of those with autoimmune skin diseases. Blood samples will be collected from participants with active/poorly controlled immune-mediated skin diseases and mild/latent/well-controlled immune-mediated skin diseases. A one-time sample from 15 general dermatology outpatients who do not have a known or suspected diagnosis of bullous diseases, immune-mediated dermatologic condition, or cutaneous malignancy will also be collected to serve as control. Blood samples from both participant populations will be analyzed for coagulation and inflammatory markers and compared. The results of this study may help inform future studies on the utility of analyzing coagulation and fibrinolysis profiles of patients with autoimmune skin diseases.

Eligible Conditions
  • Pemphigus Vulgaris

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Activated partial thromboplastin time
International normalized ratio
Thromboelastography
+1 more

Side effects data

From 2017 Phase 2 trial • 14 Patients • NCT01437488
64%
Fatigue
43%
Diarrhea
36%
Constipation
36%
Anemia
36%
Nausea
21%
Creatinine Increased
21%
Lightheadedness
21%
Vomiting
21%
Hypokalemia
14%
Abdominal Pain
14%
Back Pain
14%
Dizziness
14%
Fever
14%
Flu-Like symptoms
14%
Hypomagnesia
14%
Pinching sensation around port
14%
Shortness of Breath
14%
URI
14%
Abdominal cramping
14%
Insomnia
14%
Thrombocytopenia
7%
Blood in Bilirubin increased
7%
Dry Skin
7%
Decreased Appetite
7%
Bloating
7%
Sacral Edema
7%
Tinnitus
7%
Tearing
7%
Acid Reflux
7%
INR increased
7%
Embolic stroke
7%
Pulmonary Embolism
7%
Anorexia
7%
Anxiety
7%
Dyspnea
7%
Dysuria
7%
Fall
7%
Flatulence
7%
Foot Pain
7%
Hematoma
7%
Leg pain
7%
Loose Stools
7%
mild-mod Congestion
7%
Neutrophil count decreased
7%
Neuropathy
7%
Rib pain
7%
Throat discomfort
7%
Urinary incontinence
7%
Urinary Tract Obstruction
7%
Worsening pain
7%
Vision changes
7%
Hypoxia
7%
Abdominal distention
7%
Alkalosis
7%
Bladder Spasm
7%
Blurred Vision
7%
Bone Pain
7%
Cabazitaxel Infusion reaction
7%
Change in Taste
7%
Epigastric Pain
7%
Hematuria
7%
Hypophosphatemia
7%
Hypertension
7%
Pain in Pelvis
7%
Paresthesia bilateral feet
7%
Perioral numbness
7%
Peripheral Neuropathy
7%
Weakness
7%
Weight loss
7%
Tachycardia
7%
Bleeding Gums
7%
PTT prolonged
7%
Pyelonephritis
7%
Rash
100%
80%
60%
40%
20%
0%
Study treatment Arm
Cabazitaxel

Trial Design

2Treatment groups
Experimental Treatment
Group I: Without immune-mediated dermatologic conditionExperimental Treatment1 Intervention
Participants without an immune-mediated dermatologic condition
Group II: Immune-mediated conditionExperimental Treatment1 Intervention
Participants with an immune-mediated condition
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Blood Draw
2006
Completed Phase 4
~2400

Find a Location

Who is running the clinical trial?

University of NebraskaLead Sponsor
536 Previous Clinical Trials
1,143,883 Total Patients Enrolled
Erin X Barrett, MDPrincipal InvestigatorUniversity of Nebraska

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~22 spots leftby Aug 2025